Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioScrip, McKesson Among Bidders For Next Medicare Part B CAP Contract

Executive Summary

February 15 marked the closing date for potential vendors to submit bids to provide Part B drugs under the Medicare competitive acquisition program for the years 2009-2011, with two companies confirmed as participating in the process

You may also be interested in...



CMS Suspends Part B CAP As Vendors Avoid Program; Overhaul May Follow

The competitive acquisition program for Medicare Part B drugs and biologics will be put on hold in 2009 because of a lack of interest among specialty drug distributors in becoming approved vendors

CMS Suspends Part B CAP As Vendors Avoid Program; Overhaul May Follow

The competitive acquisition program for Medicare Part B drugs and biologics will be put on hold in 2009 because of a lack of interest among specialty drug distributors in becoming approved vendors

CMS Proposes Lifting CAP’s Ban On Physicians Transporting Part B Drugs

CMS is proposing to do away with its restriction against physicians transporting from one location to another the drug products obtained through Medicare Part B's competitive acquisition program

Related Content

UsernamePublicRestriction

Register

PS049304

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel